文献速递免疫规划慢病防控与筛查卫生政策与健康促进

西班牙加泰罗尼亚中老年人肺炎球菌疫苗接种覆盖率:2017年按年龄、性别及特定基础风险状况分析

Pneumococcal vaccination coverages by age, sex and specific underlying risk conditions among middle-aged and older adults in Catalonia, Spain, 2017.
PubMed 文献 · Euro Surveill · 2019-01-01

基于加泰罗尼亚健康研究所管理的初级保健中心2017年1月1日数据,纳入2,057,656名≥50岁人群进行回顾性观察研究。PPsV23总体覆盖率为38.7%,PCV13为0.7%;覆盖率随年龄增长而升高(p<0.001),性别间无实质差异。公共卫生资助目标人群中PPsV23覆盖率为52.8%,PCV13为3.3%,总体接种覆盖率不理想。

要点

  • PPsV23总体覆盖率38.7%,PCV13仅0.7%,PCV13覆盖率明显不足。
  • PPsV23覆盖率随年龄升高:50-64岁9.2%,65-79岁63.1%,≥80岁81.2%(p<0.001)。
  • 公共卫生资助目标人群中PPsV23覆盖率达52.8%,PCV13仅3.3%。

核心结论

  • 加泰罗尼亚≥50岁成人肺炎球菌疫苗接种覆盖率不理想,尤其是PCV13。

研究设计与样本

  • 基于人群的回顾性观察研究,纳入2017年1月1日加泰罗尼亚健康研究所管理的初级保健中心中2,057,656名≥50岁个体。
  • 使用机构临床研究数据库(SIDIAP)按PPsV23和PCV13接种状态分类并识别基础风险状况。

主要发现

  • 796,879人(38.7%)接种PPsV23,13,607人(0.7%)接种PCV13。
  • PPsV23覆盖率随年龄升高:50-64岁9.2%(95,409/1,039,872),65-79岁63.1%(434,408/688,786),≥80岁81.2%(267,062/328,998),p<0.001。
  • PCV13覆盖率随年龄升高但各年龄段均较低:50-64岁0.4%(4,250/1,039,872),65-79岁0.9%(6,005/688,786),≥80岁1.0%(3,352/328,998),p<0.001。
  • 性别间未见实质性覆盖率差异。
  • 公共卫生资助PPsV23目标人群(<65岁至少有一种风险因素者加所有≥65岁成人)覆盖率为52.8%(771,722/1,462,261);PCV13资助目标(全年龄段免疫受损者)覆盖率为3.3%(6,617/202,348)。

临床怎么用

  • 应重点关注PCV13接种覆盖率极低的现状,尤其在免疫受损等高风险人群中加强接种推荐。
  • 对50-64岁人群及合并慢性心、肾、肺疾病者,应主动评估肺炎球菌疫苗接种状态并补种。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BackgroundRecent published data on pneumococcal vaccination coverages among adults are scarce.AimTo update on pneumococcal vaccination uptakes among middle-aged and older adults in Catalonia.MethodsWe conducted a population-based retrospective observational study including 2,057,656 individuals ≥ 50 years old assigned to primary care centres managed by the Catalonian Health Institute on 1 January 2017 (date of data collection). An institutional clinical research database (SIDIAP) was used to classify persons by vaccination status for both 23-valent pneumococcal polysaccharide (PPsV23) and 13-valent pneumococcal conjugate (PCV13) vaccines, as well as to identify underlying risk conditions.ResultsOverall, 796,879 individuals (38.7%) had received PPsV23 and 13,607 (0.7%) PCV13. PPsV23 coverage increased with age: 9.2% (95,409/1,039,872) in 50-64 year olds, 63.1% (434,408/688,786) in 65-79 year olds and 81.2% (267,062/328,998) in ≥ 80 year olds (p < 0.001). PCV13 coverage also increased with age, although percentages were smaller in all age strata (4,250/1,039,872: 0.4%; 6,005/688,786: 0.9% and 3,352/328,998: 1.0%, respectively; p < 0.001). By sex, no substantial coverage differences were observed. Considering publically funded target groups for PPsV23 vaccination in Catalonia (i.e. < 65 year olds with at least one risk factor, plus all adults aged ≥ 65 years), PPsV23 coverage reached 52.8% (771,722/1,462,261) in our study population. Regarding PCV13 publicly funded targets (i.e. all-age immunocompromised persons), PCV13 coverage was 3.3% (6,617/202,348). By risk conditions, the highest PPsV23 coverage appeared in congestive heart failure (51,909/63,596; 81.6%), chronic renal disease (122,791/158,726; 77.4%) and chronic bronchitis/emphysema (96,453/132,306; 72.9%). Maximum PCV13 coverage appeared in cirrhosis (294/7,957; 3.7%), chronic renal disease (5,633/158,726; 3.5%) and chronic bronchitis/emphysema (2,859/132,306; 2.2%).ConclusionPneumococcal vaccination coverages in Catalonian adults are suboptimal, especially for PCV13.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Vila-Córcoles A, Ochoa-Gondar O, de Diego C, et al. Pneumococcal vaccination coverages by age, sex and specific underlying risk conditions among middle-aged and older adults in Catalonia, Spain, 2017. Euro Surveill. 2019. PMID: 31339099. doi:10.2807/1560-7917.ES.2019.24.29.1800446

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。